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Abstract
Although treatment of multiple sclerosis (MS) with the type I interferon (IFN) IFN-b lowers disease activity, the role of
endogenous type I IFN in MS remains controversial. We studied CD4+ T cells and CD4+ T cell subsets, monocytes and
dendritic cells by flow cytometry and analysed the relationship with endogenous type I IFN-like activity, the effect of IFN-b
therapy, and clinical and magnetic resonance imaging (MRI) disease activity in MS patients. Endogenous type I IFN activity
was associated with decreased expression of the integrin subunit CD49d (VLA-4) on CD4+CD26
high T cells (Th1 helper cells),
and this effect was associated with less MRI disease activity. IFN-b therapy reduced CD49d expression on CD4+CD26
high T
cells, and the percentage of CD4+CD26
high T cells that were CD49d
high correlated with clinical and MRI disease activity in
patients treated with IFN-b. Treatment with IFN-b also increased the percentage of CD4+ T cells expressing CD71 and HLA-
DR (activated T cells), and this was associated with an increased risk of clinical disease activity. In contrast, induction of CD71
and HLA-DR was not observed in untreated MS patients with evidence of endogenous type IFN I activity. In conclusion, the
effects of IFN-b treatment and endogenous type I IFN activity on VLA-4 expression are similar and associated with control of
disease activity. However, immune-activating effects of treatment with IFN-b may counteract the beneficial effects of
treatment and cause an insufficient response to therapy.
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Introduction
The type I interferons (IFNs) IFN-a and IFN-b are produced in
response to viral infections and induce changes in cellular function
by binding to specific receptors on the cell surface, resulting in the
induction or repression of numerous genes and a wide range of
antiviral and immunological effects [1,2]. Treatment with
recombinant interferon IFN-b decreases disease activity in
relapsing-remitting multiple sclerosis (MS) by approximately
30% [3–5].
Recent studies have identified an endogenous type I IFN gene
expression signature in a subgroup of untreated patients with MS
[6,7]. This response has been linked with expression of the
immunoregulatory cytokine interleukin (IL)-10, the immunoregu-
latory transcription factor FoxP3 and protection from disease
activity in untreated MS patients and during subsequent treatment
with IFN-b [8–10]. Furthermore, the expression of IL-10 is lower
in patients who have developed neutralizing antibodies to IFN-b
than in other untreated MS patients and healthy control subjects,
suggesting that endogenous IFN-b is involved in the induction of
IL-10 [9]. Other studies have, however, suggested that the
expression of IFN-stimulated genes in untreated MS patients is
associated with a diminished capacity to induce IFN-stimulated
genes and a higher risk of breakthrough disease upon subsequent
treatment with exogenous IFN-b [11]. The reason for these
differences, which indicate completely different roles of endoge-
nous and exogenous IFN-b in the pathogenesis of MS, is
unknown.
To further explore this subject, we compared the effect of IFN-b
treatment with the effects associated with evidence of endogenous
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e35927type I IFN activity on CD4+ T cell and T cell subset activation,
monocyte and DC activation and clinical and magnetic resonance
imaging disease activity in MS. The CD4+ T cell subsets studied
were identified according to their expression of CD25 (the IL-2
receptor a-chain) and CD26. CD25 is expressed at high levels on
regulatory T cells but also on highly activated effector T cells
[12,13]. CD26 expression identifies a subset of CD4+ T cells with
a T helper type 1 (Th1) phenotype previously implicated in the
pathogenesis of MS [14–17]. This study identifies parallels
between the effects of endogenous type I IFN-like activity and
the effects of treatment with IFN-b that are associated with a
reduction in disease activity. However, IFN-b therapy is also found
to have additional effects on circulating T cells, some of which are
associated with an unexpected increase in the risk of disease
activity.
Materials and Methods
Patient Material
The study was approved by the regional ethics committee of
Copenhagen and Frederiksberg (KF01–041/95). All patients
provided written informed consent. Venous blood samples were
obtained from 39 untreated patients with relapsing-remitting MS
of whom 24 subsequently began treatment with IFN-b (IFN-b1a
30 mg once weekly in 19 patients, IFN-b1a 44 mg three times
weekly in 4 patients and IFN-b1b 250 mg every other day in one
patient). These patients were followed with serial blood samples
after three and six months of therapy [8]. One patient who
developed neutralizing anti-IFN-b antibodies after six months of
therapy was excluded from the subsequent analysis. Blood samples
from this cohort were obtained 9–12 hours after an injection of
IFN-b. In addition, we studied 40 patients who had been treated
with IFN-b for at least six months (including 14 patients who were
also included in the first cohort); 20 of these patients were treated
with IFN-b1a 30 mg once weekly and 20 received IFN-b1a 44 mg
three times weekly. Blood samples from these patients were
obtained 36–48 hours after an injection of IFN-b. Further
description of the cohorts is presented in Table 1. A control
group consisting of 12 healthy volunteers (8 women and 4 men;
median age 31 years, range 26–46 years) was also included in the
study.
Assessment of Disease Activity
Clinical activity was defined as the occurrence of a confirmed
relapse (new or recurrence of previous symptoms of MS lasting
.24 hours, in the absence of fever or signs of systemic infection,
and with findings on neurological examination consistent with the
symptoms). All patients were followed up with biannual control
visits for one year and acute visits in case of new symptoms
suggesting a relapse. Time to first relapse was established for all
patients.
Magnetic Resonance Imaging
MRI was performed using a 3.0 T whole body scanner (Trio,
Siemens, Erlangen, Germany), maximum gradients 40 mT/m, 8-
channel head coil within one week of all blood samplings [8]. To
quantify the lesion load, fluid-attenuated inversion recovery
(FLAIR) and proton density/T2 weighted 2D imaging sequences
were used. A T1-weighted 3D imaging sequence (Magnetization
Prepared RApid Gradient Echo (MPRAGE) was acquired
approximately 15 minutes post-intravenous gadolinium (Gd)
administration (0.2 mmol/kg body weight of Magnevist (Schering
AG, Berlin, Germany)). T2 lesions and enhancing lesions were
detected and counted by an experienced technician using in-house
developed software.
Flow Cytometry Analysis of CD4+ T Cells and Antigen-
presenting Cells
A lyse-and-wash whole blood staining procedure, where whole
blood samples were stained with a cocktail of pretitrated
fluoresceinated monoclonal antibodies, lysed, washed and ana-
lyzed on a BD FACSCalibur
TM flow cytometer, was used to
analyse CD4+, CD25
high and CD26
high T cells and CD14+
monocytes. Staining with anti-HLA-DR, a lineage antibody
cocktail, anti-CD11a (expressed on myeloid dendritic cells) and
anti-CD123 (expressed on plasmacytoid dendritic cells) antibodies
were used for the identification of dendritic cells. Isotype control
reagents and unstained controls were used to control for non-
specific antibody binding and autofluorescence. Analysis of list-
mode files was conducted with the BD FACSDiva
TM software
(Becton Dickinson). A list of all surface markers studied is given in
Table S1.
In vitro Analysis of T Cell Activation
Blood mononuclear cells (MNCs) were isolated from heparin-
ised venous blood from 11 healthy volunteers using density
gradient centrifugation of heparinised venous blood on Lympho-
prep. All incubations were performed at 37uC with 5% CO2 in
RPMI1640 medium (Invitrogen, Taastrup, Denmark) supple-
mented with 5% human serum albumin. The cells were cultured
for 24 hours in 6-well plates at a concentration of 2610
6 cells/ml
with 1 ng/ml recombinant human IFN-b1a (Avonex, Biogen-
Idec, Cambridge, MA, USA), 10 ng/ml 6-a-methylprednisolone
(MP) dissolved in dimethylsulfoxide (Sigma), IFN-b1a and MP, or
none of these drugs. After 24 hours the cells were washed, and
Table 1. Overview of the patient material.
Untreated (n=39)
Interferon-treated (early cohort,
n=23)
Interferon-treated (late cohort,
n=40)
Median age (range) 33 years (23–53) 30 years (23–46) 33 years (23–57)
Gender 24 women/15 men 15 women/8 men 26 women/14 men
Median duration of disease 4 years (1–25) 2 years (1–12) 5.5 years (1–20)
Median Kurtzke EDSS score (range) 2.0 (0–6.0) 1.0 (0–6.0) 2.0 (0–6.0)
Duration of treatment – – 2 years (0.5–9.5)
Median relapse rate year prior to study
inclusion (range)
1/year (0–4) 1/year (0–4) 0/year (0–4)
doi:10.1371/journal.pone.0035927.t001
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annexin V binding (a measure of apoptotic cell death) was
measured by flow cytometry and FOXP3 gene expression was
measured by PCR analysis.
Gene Expression Analysis
Expression of MX1 (encoding the type I interferon-induced
myxovirus resistance A molecule), FOXP3 and the chemokine
CXCL10 was measured in whole blood cells or cultured MNCs by
quantitative real-time polymerase chain reaction (PCR) analysis as
previously described [9,18].
Statistical Analysis
The sample size was based on previous studies on the effects of
IFN-b in small patient cohorts and on studies reporting that gene
expression profiling in 22 MS patients could identify subgroups
with different disease courses during treatment with IFN-b [19–
21]. Values are given as median with inter-quartile range.
Statistical testing was by the Wilcoxon test, the Mann-Whitney
U-test, paired t-test, non-parametric correlation analysis (Spear-
man rank correlation coefficient [SRCC]), Cox regression analysis
(hazard ratio with 95% confidence interval), the log-rank test and
Kaplan-Meier plots. P,0.05 (two-sided testing) was considered
significant; a Bonferroni correction was applied to post-hoc Man-
Whitney tests after Wilcoxon analyses.
Results
Circulating APCs and CD4+ T Cells
Anti-CD25 and anti-CD26 antibody staining identified a
population of CD25
high CD4+ T cells with intermediate expres-
sion of CD26 and a population of CD26
high CD4+ T cells with
intermediate expression of CD25 (Figure S1). The CD4+CD25
high
population constituted 2.1% (IQR 0.5%) of CD4+ T cells and the
CD4+CD26
high population constituted 12% (IQR 6.8%) of the
CD4+ T cells in blood from healthy controls. There was no
difference in the percentage of these subsets between MS patients
and controls, but MS patients had a higher percentage of
CD4+CD25
high T cells expressing CCR5 (Figure S2). MS patients
also had a higher percentage of DCs expressing CD80 than did
healthy controls (Figure S2). There was no difference in the
absolute number of circulating leukocytes, lymphocytes, mono-
cytes, dendritic cells, CD3+ T cells or CD4+ T cells in untreated
MS patients and healthy controls, and the expression of all other
molecules studied was comparable in untreated MS patients and
healthy controls (data not shown).
Endogenous Type I IFN Activity in Untreated MS
The expression of MX1 mRNA was associated with a type I
IFN-induced gene expression signature in 36 of the untreated MS
patients included in the present study [9]. The percentage of
CD4+CD26
high T cells that were CD49d
high correlated negatively
with expression of MX1 mRNA in blood cells (Figure 1).
Expression of FOXP3 in blood cells also correlated negatively
with the percentage of CD49d
high CD4+ T cells (SRCC=20.50,
p=0.002), whereas there was no correlation with IL10 expression
(data not shown). There were no other significant relationships
between MX1 gene expression and CD4+ T cell or APC
activation, but the expression of MX1 correlated with expression
of the chemokine CXCL10 (Figure 1) which, in turn, correlated
negatively with the percentage of CD4+CD26
high T cells that
expressed the CXCL10 receptor CXCR3 (Figure 1).
Figure 1. T cell activation, CXCL10 and MX1 expression. The
relationship between the percentage of CD4+CD26
high Tc e l l s
expressing CD49d or CXCR3 and the expression of MX1 and CXCL10
mRNA in blood mononuclear cells from untreated patients with
relapsing-remitting multiple sclerosis was analysed by Spearman rank
correlation coefficients (SRCC).
doi:10.1371/journal.pone.0035927.g001
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Treatment with IFN-b transiently decreased the number of
circulating lymphocytes, dendritic cells and CD3+ and CD4+
T cells and increased the number of monocytes 9–12 hours after
an injection of IFN-b (Table S2). These effects were not observed
36–48 hours post-injection. Other effects of IFN-b were persistent
as they were observed both 9–12 and 36–48 hours after an
injection of IFN-b: an increased percentage of CD4+ and
CD4+CD25
high T cells expressing CD71; an increased percentage
of CD4+ T cells expressing HLA-DR; a decreased percentage of
CD4+CD26
high T cells that were CXCR3+ or CD49d
high;a n
increased percentage of monocytes expressing CD86; and a
decreased percentage of dendritic cells expressing CCR5 (Table
S2). Other statistically significant effects observed either 9–12 or
36–48 hours post-injection are summarized in Table S2. There
were no significant differences between the patients treated with
IFN-b1a 30 mg once weekly and patients treated with IFN-b1a
44 mg three times weekly.
IFN-b Treatment and MRI Disease Activity
At the six months scan 7/23 patients (30%) had one or more
Gd-enhancing lesions on MRI (median 1, range 1–12 lesions) and
15/23 patients had one or more new or enlarged T2-weighted
MRI lesions during the six months of follow-up (median 3, range
1–27 lesions). The relationship between the number of Gd-
enhancing lesions at month 6 and the number of new or enlarged
T2 lesions and the immunological variables is shown in Table 2.
The percentage of CD4+CD26
high T cells that were CD49d
high
correlated positively with the number of Gd-enhancing MRI
lesions (SRCC=0.58, p=0.006) and the number of new or
enlarged T2 lesions (SRCC=0.46, p=0.042). The percentage of
CD4+CD25
high T cells that were CD137+ correlated negatively
with the number of Gd-enhancing lesions (SRCC=20.47,
p=0.025) and the number of new or enlarged T2 lesions
(SRCC=20.64, p=0.001).
IFN-b Treatment and Clinical Disease Activity
In univariate Cox regression analyses the one-year relapse risk
was associated with several variables in samples obtained early
after an injection of IFN-b after 6 months of treatment: the
percentage of dendritic cells expressing CD40 and CD80; the
percentage of CD4+ T cells that were CD62L
high or expressed
CD71, CD95 or HLA-DR; the percentage of CD4+CD25
high cells
that expressed CD137; and the percentage of CD4+CD26
high cells
that were CD49d
high (Table 2). In multivariate analyses the
percentage of CD4+ T cells expressing HLA-DR (hazard ratio
1.89 [1.13–3.16], p=0.015) and the percentage of dendritic cells
expressing CD40 (hazard ratio 1.84 [1.16–2.90], p=0.009) were
independent predictors of relapse risk. Although MRI disease
activity was associated with relapse risk in a univariate analysis [8],
Gd-enhancing MRI lesions were not an independent predictor of
relapse risk. Neither did baseline flow cytometry results correlate
with disease activity on subsequent treatment with IFN-b (data not
shown).
The relationship between CD40 expression on dendritic cells
and HLA-DR expression on CD4+ T cells and relapse risk was
further analysed in the 40 patients from whom blood samples were
obtained 36–48 hours after an injection of IFN-b. In this cohort
there was no relationship between CD40 expression on dendritic
cells and relapse risk. However, patients with a percentage of
HLA-DR positive CD4+ T cells above median had a higher
relapse risk than patients with below median values (Figure 2).
This relationship was highly significant in patients with a disease
duration of less than 5 years (n=19, p=0.003) and in patients
treated with IFN-b for less than two years (n=21, p=0.004)
(Figure 2). Gd-enhancing MRI lesions were observed in 10/40 of
these patients but were not an independent predictor of relapse
risk in the multivariate analysis.
Correlation between Flow Cytometry Measurements
Comparing values obtained 9–12 hours after an injection of
IFN-b after six months of treatment we found moderate positive
correlations (SRCC.0.5) between the percentage of CD4+ T cells
expressing CD95 and HLA-DR (SRCC=0.71, p,0.001) and
CD71 (SRCC=0.73, p,0.001); between the percentage of
CD4+CD25
high T cells expressing CD137 and the percentage of
CD4+ T cells that were CD62L
high; and a negative correlation
between the percentage of CD4+CD25
high T cells expressing
CD137 and the percentage of CD4+CD26high T cells that were
CD49d
high.
Table 2. Immune activation and disease activity.
Hazard ratio of relapse Gd-enhancing lesions New or enlarged T2 lesions
Dendritic cells
CD40 positive (%) 1.39 (1.12–1.73), p=0.003 0.31, NS 0.42, NS
CD80 positive (%) 1.10 (1.01–1.20), p=0.033 0.30, NS 0.11, NS
CD4+ T cells
CD62L
high 0.83 (0.69–1.00), p=0.049 20.24, NS 20.51, p=0.023
CD71+ 1.38 (1.10–1.73), p=0.005 0.11, NS 0.05, NS
CD95+ 1.18 (1.04–1.34), p=0.009 0.10, NS 0.03, NS
HLA-DR+ 1.32 (1.06–1.63), p=0.014 0.00, NS 0.16, NS
CD4+CD25
high T cells
CD137+ 0.68 (0.51–0.91), p=0.009 20.47, p=0.025 20.64, p=0.001
CD4+CD26
high T cells
CD49d
high 1.21 (1.01–1.43), p=0.029 0.58, p=0.006 0.46, p=0.042
Relapse risk, magnetic resonance imaging disease activity, T cell and dendritic cell activation in blood samples obtained 9–12 hours after an injection of interferon-b in
23 MS patients treated with interferon-b for six months.
doi:10.1371/journal.pone.0035927.t002
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analysed by comparing the results of the flow cytometry
measurements after three and six months of therapy. The
percentage of CD4+ T cells expressing HLA-DR (SRCC=0.71,
p,0.001), CD95 (SRCC=0.51, p=0.027) or that were
CD62L
high (SRCC=0.63, p=0.003) correlated after three and
six months of therapy (data not shown). There were no significant
correlations between month 3 and month 6 results for the other
variables studied.
In vitro Studies of T Cell Activation by Interferon-b
The effect of IFN-b and MP on CD4+ T cells was studied after
24 hours of in vitro treatment of MNCs from healthy volunteers
(Table 3). Treatment with IFN-b or IFN-b in combination with
MP did not affect the viability of the cells as assessed by annexin V
staining, but MP increased the percentage of annexin V-binding
CD4+ T cells (p,0.001). Incubation with IFN-b increased the
percentage of CD4+ T cells that were CD25+ (p,0.001),
CD25
high (p,0.001) and CD71+ (p=0.01) and the expression of
FOXP3 mRNA in MNCs (p=0.005) compared with untreated
cells. Treatment with MP alone reduced the percentage of CD4+
T cells that were CD25
high (p=0.002) or CD71+ (p=0.011) and
reduced FOXP3 expression (p=0.024) compared with untreated
cells. Combination treatment with IFN-b and MP increased the
percentage of CD4+ that cells that were CD25+ T cells but had no
effect on CD25
high or CD71+ CD4+ T cells or FOXP3 mRNA
expression.
Discussion
The major findings in the present study are that: 1) endogenous
type I IFN-like activity and treatment with IFN-b are both
associated with reduced expression of CD49d on CD26
high CD4+
T cells (Th1 helper cells) and this correlates with MRI disease
activity in IFN-b-treated MS patients; 2) treatment with IFN-b
also induces activation of CD4+ T cells, as evidenced by the
induction of CD71 and HLA-DR, and this is associated with an
increased relapse risk.
CD4+CD26
high T cells are enriched for expression of Th1
markers and produce high levels of tumour necrosis factor (TNF)-
a and IFN-c [14,15]. Disease activity in relapsing-remitting MS
and in patients with clinically isolated syndromes is associated with
an increased percentage of circulating CD4+CD26+ T cells
[14,16,17]. These findings indicate that CD26
high T cells are a
potential target for immunomodulatory MS treatments, and in a
previous study we found that the number of circulating T cells,
especially CD4+CD26+ T cells, predicted relapses in MS patients
treated with IFN-b [22]. CD49d is an integrin a-chain that
together with the integrin b-chain CD29 molecule forms very late
antigen (VLA)-4. The role of VLA-4 in the pathogenesis of MS is
clearly evidenced by the efficacy of treatment with the anti-CD49d
molecule natalizumab. CD49d is expressed at high levels on
CD4+CD26
high T cells, and CD4+CD49d
high T cells are increased
in patients with active MS [15,23]. IFN-b decreases the expression
of CD49d in MS [20,24]. We extend these findings by showing
that a decrease in CD49d
high cells is found mainly in
Figure 2. T cell activation and relapse risk. Relationship between
CD4+ T cell expression of HLA-DR and relapse risk in 39 patients from
whom blood samples were obtained 36–48 hours after an injection of
interferon-b. Patients were dichotomized around the median and
relapse risk was analysed in Kaplan-Meier plots and with the log-rank
test in all patients and in subgroups of patients with a shorter duration
of treatment or disease duration.
doi:10.1371/journal.pone.0035927.g002
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high cells in patients treated with IFN-b and that
endogenous type I IFN activity, as assessed by expression of MX1,
correlates negatively with the percentage of CD4+CD26
high T cells
that are CD49d
high. These findings suggest that not only IFN-b
treatment but also endogenous type I IFN may exert immuno-
regulatory effects on CD49d, either directly or by indirect effects
such as induction of soluble adhesion molecules [24].
The CCR5 and CXCR3 chemokine receptors are expressed
on Th1 effector cells and are thought to be involved in the
development of inflammatory brain lesions in MS while CCR7 is
expressed on naive and central memory T cells. The decrease in
CCR5 and CXCR3 expression and the concomitant increase in
CCR7 expression observed on CD4+CD26
high T cells in MS
patients treated with IFN-b in the present study are consistent
with reduced activation or a transition of cells within this T cell
subset from tissue-homing effector cells to the central memory T
cell subset. Indeed, treatment with IFN-b also reduced the
expression of CD122 (the IL-2 receptor b-chain), CD134
(OX40), CD137 (4–1BB) and CD212 (the IL-12 receptor b2
chain) on CD4+ CD26
high T cells.
The observation of an increased percentage of HLA-DR and
CD71 positive CD4+ Tc e l l sa f t e rin vivo treatment with IFN-b is
a novel observation, which was confirmed in vitro for the CD71
induction on CD4+ Tc e l l s .I F N - b has previously been reported
to induce the expression of activation markers on CD8+ T cells
in MS [21,25]. This is consistent with the results of studies
demonstrating that type I IFN can enhance antiviral cytotoxic T
cell and NK cell responses, i.e., an immune activating effect of
type I IFN [1,26]. Furthermore, although the ex vivo prolifer-
ation of CD4+ T cells is suppressed by type I IFNs, in vivo CD4+
T cell responses to some viruses are markedly enhanced by type
I IFN signalling, and type I IFNs can promote the survival of T
cells and enhance the differentiation of memory Th1 cells [27];
[28–30].
In our study the percentage of CD4+ HLA-DR+ T cells was an
independent predictor of relapse risk both in patients from whom
samples were obtained 9–12 hours and in patients from whom
samples were obtained 36–48 hours after an injection of IFN-b.I n
the latter cohort this relationship was highly significant in patients
studied within the first five years from onset of MS and during the
firsttwoyearsoftreatmentbutnotinthefullpatientmaterial.Thisis
likely to reflect that a more pristine patient population may be less
selected than patients on long-term therapy, and therefore better
suited for biomarker studies of the treatment response in MS.
We observed a negative correlation between the percentage of
CD4+CD25
high T cells expressing CD137 and clinical and MRI
disease activity, consistent with the notion that this marker may
reflect regulatory T cell activity [31]. We did, indeed, find that in
vitro treatment with IFN-b increased the percentage of CD4+ T
cells that were CD25
high and expression of FOXP3 mRNA. It
should, however, be emphasized that the CD4+CD25
high T cell
subset in MS consists of a mixture of highly activated effector cells
and regulatory T cells, and functional studies are needed to
substantiate a possible regulatory effect of CD4+CD25
high T cells
expressing CD137 in MS [13].
We observed a relationship between CD40 expression on
dendritic cells and relapse risk in patients from whom blood
samples were obtained 9–12 hours after an injection of IFN-b, but
this was not confirmed in samples obtained 36–48 hours after an
injection of IFN-b. The number of circulating dendritic cells was
significantly reduced at the early time point and additional studies
using more sophisticated phenotyping of dendritic cell subsets are
necessary to establish the relationship between the effects on these
cells and disease activity. We could not confirm that the induction
of CD40, CD86 and PD-L2 on monocytes is associated with a
beneficial response to treatment with IFN-b [32].
Finally the results highlight the importance of consistent timing
of blood sampling in relation to IFN-b injections as many changes
observed 9–12 hours after an injection of IFN-b were not observed
36–48 hours post injection. The effects of IFN-b on gene
expression are mainly transient, and some of these may translate
into transient changes in the expression of cell surface molecules
[18,33,34]. We observed a marked reduction in expression of the
chemokine receptor CXCR3 expression 9–12 hours after an
injection of IFN-b in all CD4+ T cell subsets studies. This may
result from increases in plasma concentrations of the CXCR3
ligand CXCL10 [35,36]. Indeed, in untreated MS patients we
found that the expression of CXCL10 mRNA correlated with the
expression of the type I IFN-induced MX1 molecule. Furthermore,
high CXCL10 mRNA expression correlated with low CXCR3
expression on CD4+ T cells, suggesting that CXCL10 induced by
endogenous type I IFN may regulate physiological T cell
expression of CXCR3.
We conclude that the modulation of CD49d and other
molecules on CD4+CD26high T cells may be one of the most
important effects of IFN-b in MS, and may also be mediated by
endogenous type I IFN activity. Conversely, the induction of
HLA-DR and CD71 may reflect an unwanted, immune activating
effect of IFN-b associated with an increased relapse risk. The
induction of CD71 by IFN-b was preventable by combination
treatment with methylprednisolone in vitro. It is tempting to
speculate that this may contribute to the efficacy of combination
therapy with methylprednisolone and IFN-b, which significantly
reduces the relapse rate in MS compared with IFN-b alone
[37,38]. However, these conclusions are based on studies in small
patient cohorts. Larger studies identifying the mechanisms
underlying the relationship between T cell activation induced by
IFN-b and relapse risk will be important not only for improving
Table 3. Ex vivo effect of interferon-b1a and methylprednisolone.
Control IFN-b MP IFN-b and MP
CD4+Annexin V+ 5.6% (1.4) 5.0% (2.3), NS 8.9% (1.5), p,0.001 6.0% (1.7), NS
CD4+CD25+ 21% (2.3) 26% (2.3), p,0.001 20% (1.9), NS 24% (2.7), p=0.007
CD4+CD25
high 2.8% (0.23) 3.7% (0.39), p,0.001 1.9% (0.22), p=0.002 3.1 (0.26), NS
CD4+CD71+ 0.54% (0.11) 0.77% (0.22), p=0.01 0.40% (0.08), p=0.011 0.44% (0.07), NS
FOXP3 mRNA 2.8 (0.7) 6.2 (1.2), p=0.005 0.93 (0.86), p=0.024 2.0 (1.3), NS
Effect of ex vivo treatment of blood mononuclear cells (MNCs, n=11) with interferon-b1a (IFN-b) and/or methylprednisolone (MP) for 24 hours on surface expression of
CD25 and CD71 on CD4+ T cells and expression of FOXP3 mRNA.
doi:10.1371/journal.pone.0035927.t003
Type I IFN in Multiple Sclerosis
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also for understanding what may be a natural, immunoregulatory
role of type I IFN activity in MS.
Supporting Information
Figure S1 Principles for flow cytometry analysis. CD4+
T cells were idenfied according to light scatter and anti-CD4
antibody fluorescence intensity, and were subdivided into a
CD25
high and a CD26
high subset according to anti-CD25 and
anti-CD26 fluorescence intensity. Finally, the percentage of CD4+
T cells, CD25
high and CD26
high CD4+ T cells expressing a panel
of antigens was measured against an isotype control antibody (anti-
CD49d staining in this example).
(DOC)
Figure S2 Immune activation in untreated multiple
sclerosis. The percentage of CD4+CD26
high T cells expressing
CCR5 and the percentage of dendritic cells expressing CD80 was
significantly higher in untreated multiple sclerosis without (Gd-)
and with (Gd+) gadolinium-enhancing lesions magnetic resonance
imaging lesions in the brain than in healthy control subjects.
Statistical testing was by the Mann-Whitney U-test.
(DOC)
Table S1 Surface markers studied by flow cytometry.
This table lists the molecules studied by flow cytometry and their
biological functions on T cells and antigen-presenting cells.
(DOC)
Table S2 Flow cytometry results. Circulating cell counts,
CD4+ T cell subsets, monocytes and dendritic cells in untreated
MS patients (n=39) and patients treated with interferon-b. Blood
samples were obtained either 9–12 hours (early, n=23) or 36–48
hours (late, n=40) post-injection. Values are medians (inter-
quartile range). Statistical testing was by Kruskal-Wallis tests for
comparing the three groups groups. Mann-Whitney U-tests were
used for post-hoc analysis with Bonferroni-corrected p-values
(comparing each treatment group with untreated patients).
NS=not significant. p,0.05*, p,0.01**, p,0.001***
(DOC)
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